A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome

• Published in: Expert opinion on pharmacotherapy Vol. 25; no. 14; p. 1953
• Main Authors: Roy, Madhura, Parveen, Rizwana, Khan, Parvej, Majid, Haya, Pathak, Mani, Saxena, Rajesh, Nidhi
• Format: Journal Article
• Language: English
• Published: England 01.10.2024
• Subjects: Blood Glucose - drug effects; Blood Glucose - metabolism; Female; Humans; Insulin Resistance; Polycystic Ovary Syndrome - drug therapy; Polycystic Ovary Syndrome - metabolism; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; sodium-glucose cotransporter 2 inhibitors; Polycystic ovarian syndrome; oral hypoglycaemic agents; insulin resistance; body mass index
• ISSN: 1744-7666
• DOI: 10.1080/14656566.2024.2407513

Polycystic ovarian syndrome (PCOS) has been a common metabolic and endocrinal disorder, prevalent amongst women belonging to the reproductive age group. The aim of this systematic review was to assess the safety and efficacy profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, and Licogliflozin) for the treatment of women suffering from PCOS. A literature search in PubMed, Science Direct, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov was conducted for randomized clinical trials of SGLT-2 inhibitors in PCOS patients by applying predetermined inclusion and exclusion criteria. The articles in English language were included. Four randomized controlled trials including 146 subjects were included in the review. The clinical studies indicated a significant decrease in the levels of total testosterone, free androgen index, total body fat, homeostasis model assessment-estimated insulin resistance (HOMA-IR), body mass index (BMI), dehydroepiandrosterone sulfate (DHEAS) and fasting plasma glucose (FPG). However, no significant difference was reported in levels of sex hormone-binding globulin (SHBG). Overall, there was improvement in metabolic and endocrine profiles, suggesting a potentially beneficial impact of SGLT2 inhibitors in the management of PCOS. There is a requirement for large extensive clinical trials to demonstrate the efficacy of SGLT-2 inhibitors in PCOS patients.